A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2658-2667

  Mross, Klaus ^a   Frost, Annette ^a   Steinbild, Simone ^a   Hedbom, Susanne ^a   Büchert, Martin ^a   Fasol, Ulrike ^a   Unger, Clemens ^a   Krätzschmar, Jörn ^b   Heinig, Roland ^b   Boix, Oliver ^b   Christensen, Olaf ^c,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c BAYER CORPORATION   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DRUG METABOLITE; REGORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRAIN HEMORRHAGE; BRONCHOSPASM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEHYDRATION; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SOLID TUMOR; SOMNOLENCE; SYNDROME DELINEATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URTICARIA; VOICE CHANGE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENIC PROTEINS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84860531989     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1900     Document Type: Article

References (29)

1. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-43.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59. (Pubitemid 47050835)
4. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-9. (Pubitemid 24060300)
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
6. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003;2: 345-51.
7. Doanes AM, Hegland DD, Sethi R, Kovesdi I, Bruder JT, Finkel T. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999;255:545-8. (Pubitemid 29292296)
8. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/ MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002;8:S27-S31. (Pubitemid 34297075)
9. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-35. (Pubitemid 34728854)
10. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001;276:49289-98.
11. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
12. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310. (Pubitemid 46763022)
13. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010;7:327-38.
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80. (Pubitemid 34879334)
15. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
16. Giordano S, Petrelli A. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32. (Pubitemid 351472408)
17. Adams J, Huang P, Patrick D. A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol 2002;6:486-92. (Pubitemid 34804772)
18. Wilhelm S, Adnane J, Lynch M, Hornberg JJ, Schütz G, Thierauch K-H, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal, and oncogenic (receptor tyrosine) kinases with potent preclinical antitumor activity. Abstract presented at the 21st International Conference on Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC, Boston, MA, November 15-19, Abs B4, 2009.
19. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry bioanalytical method validation. 2001;1-25.
21. Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 2009;1:5.
22. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-54. (Pubitemid 47218051)
23. Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41:1291-9. (Pubitemid 40813005)
24. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-9.
25. Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, et al. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer 2008;99:1579-85.
26. Zopf D, Heinig R, Thierauch K-H, Hirth-Dietrich C, Hafner F-T, Christensen O, et al. Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Abstract presented at the AACR 101st Annual Meeting, Washington DC, April 17-21, Abs 1666, 2010.
27. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84. (Pubitemid 350051025)
28. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-35. (Pubitemid 46548961)
29. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012 (in press).